Men with child bearing potential are required to use an effective means of contraception
Women of child-bearing potential using hormonal contraception, unless an additional contraception method is also used according to the Mekinist label. Additional exclusion criteria for Combination arm PDR+EGF
Of non-child-bearing potential (surgically sterilized or at least  years post-menopausal); or
If of child-bearing potential, subject must use an adequate method of contraception consisting of two-barrier method or one barrier method with a spermicide or intrauterine device. Both females and male subjects with female partners of child-bearing potential must agree to use an adequate method of contraception for  weeks prior to screening, during, and at least  weeks after last dose of study medication. Female subjects must have a negative serum or urine pregnancy test within  hours prior to start of study medication.
If female of child bearing potential, must not be lactating and must have a negative pregnancy test (blood or urine, at the discretion of the investigator) prior to enrollment and use effective contraception during study participation. Women should continue effective contraception for  months following last dose of TB-.
Female patients of child-bearing potential and male patients must agree to use adequate contraception
Of non-child-bearing potential (surgically sterilized or at least  years post-menopausal); or
If of child-bearing potential, subject must use an adequate method of contraception consisting of two-barrier method or one barrier method with a spermicide or intrauterine device. Both females and male subjects with female partners of child-bearing potential must agree to use an adequate method of contraception for  weeks prior to screening, during, and at least  weeks after last dose of trial medication. Female subjects must have a negative serum or urine pregnancy test within  hours prior to start of trial medication.
Female subjects (if of child bearing potential) and male subjects (with a partner of child bearing potential) must use medically acceptable methods of birth control before study entry, for the duration of the study, and for at least  months after the last intake of study drug.
Women of child-bearing potential (WOCBP) must agree to use an effective method(s) of contraception during treatment and during the post treatment follow-up period
Women of child-bearing potential (WOCBP) not practicing an effective method(s) of contraception.
Female participants of child-bearing potential must be willing to use effective contraception starting with the screening visit through  days after the last dose of study therapy
Females of child bearing potential and male partners of female patients must agree to use adequate contraception during the study and for  months after their last dose of study drug.
Female patients of child-bearing potential and male patients with sexual partners of child-bearing potential who are unwilling to follow strict contraception requirements before entry and throughout the study, up to and including the -day non-treatment follow-up period. Examples of acceptable contraception methods include:
Males must be surgically sterile, abstinent, or if engaged in sexual relations with a female of child-bearing potential, must be willing to use a highly effective method of contraception throughout their study participation and for at least  months after the last dose of study drug.
Of non-child-bearing potential (surgically sterilized or at least  years post-menopausal); or
If of child-bearing pIf of child-bearing potential, subject must use an adequate method of contraception consisting of two-barrier method or one barrier method with a spermicide or intrauterine device. Both females and male subjects with female partners of child-bearing potential must agree to use an adequate method of contraception for  weeks prior to screening, during, and at least  weeks after last dose of study medication. Female subjects must have a negative serum or urine pregnancy test within  hours prior to start of study medication.
Both female and male participants of child-bearing potential must agree to use highly effective contraceptive precautions during the trial and up to  months following the last dose of olaratumab, or longer for other study drugs according to their label.
Female patients who are not of child-bearing potential, and female patients of child-bearing potential who agree to use adequate contraceptive measures.
Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study
Pregnant or breast-feeding patients or any patient with child-bearing potential not using adequate contraception;
Willing to use appropriate birth control for patients of child-bearing potential;
Sexually active women of child-bearing potential must be willing to use effective contraception through month  of the study
Women of child bearing potential (WOCBP) should use an adequate method to avoid pregnancy for  months plus the time required for nivolumab to undergo approximately five half-lives) after the last dose of investigational drug; in order for a woman to be determined not of child-bearing potential, she must have >=  months of non-therapy-induced amenorrhea or be surgically sterile
Women of child bearing potential (WOCBP) must use a reliable form of contraception during the study treatment period and for up to  weeks following the last dose of study drug; in order for a woman to be determined not of child-bearing potential, she must have >=  months of non-therapy-induced amenorrhea or be surgically sterile
Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of  months after study treatment
If the patient is a woman of child-bearing potential, the patient and their sexual partner must agree to practice effective contraception
Patients of child bearing potential who are sexually active must agree to the use of two highly effective forms of contraception from the time of informed consent through  months after last dose of study drug(s)
Positive urine pregnancy test and/or breastfeeding; if a woman of child bearing potential or sexually active male, patient must be willing to use effective contraception throughout their participation in the treatment phase of the study
Subjects unwilling to use contraceptives if they have sexual intercourse with a female partner of child-bearing potential while receiving treatment on this study
Women of child bearing potential not willing to use an effective contraceptive measure while on study
Use of effective means of contraception (men and women) in subjects of child-bearing potential
Patients of child bearing potential should practice effective methods of contraception
Agreement to practice effective contraception for female subjects of child-bearing potential and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to  year after completion of therapy, and non-sterile male subjects must agree to use a condom for up to  months after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (IUDs), and abstinence.
Estimated life expectancy of at least  weeks; . Eastern Cooperative Oncology Group (ECOG) performance status ? ; . Significant toxicities incurred as a result of previous anti-cancer therapy resolved to ? Grade  (NCI-CTCAE version .); . Acceptable laboratory values at screening; . Male patients must agree to use an adequate and medically accepted method of contraception throughout the study and for at least  months after if their sexual partners are women of child bearing potential (WOCBP).
Male or female of child-bearing potential must agree to use adequate contraceptive methods
Pregnant women or nursing mothers are not eligible for this trial; patients of child bearing potential must use adequate contraception
Male or female, age  or above, who agree to use barrier contraception throughout the study. Females of child-bearing potential must be non-pregnant and non-lactating throughout the study.
Men must use adequate methods of contraception during and at least  months after treatment if engaging in sexual activity with a female of child bearing age
Women of child bearing potential who are unwilling to use effective contraception for the duration of the study drug administration and  months after final dose of drug is administered;
Women of child-bearing potential MUST have a negative serum human chorionic gonadotropin (HCG) test unless prior hysterectomy or menopause (defined as  consecutive months of amenorrhea); subjects are considered not to be of child-bearing potential if they are surgically sterilized or post-menopausal (>= years of age and has not had menses for greater than  year or with serum follicle stimulating hormone (FSH) in the menopausal range will be considered postmenopausal); subjects should not become pregnant or breastfeed while on this study; sexually active subjects of child bearing potential must agree to use contraception for the duration of study participation and for  months after the last dose of ipilimumab or nivolumab
Female subject of child-bearing potential is not willing to use, in combination with her partner,  methods of highly effective contraception during treatment and for  months after the end of treatment
Women of child-bearing potential (WOCBP) must agree to use adequate contraception when sexually active; patients should continue contraception for  months after finishing study drug
Female patients of child-bearing potential or male patients with partners of child-bearing potential who are unwilling to follow strict contraception requirements before entry and throughout the study, up to and including the -day non-treatment follow-up period.
Women of child bearing potential and men with partners of child bearing potential must agree to use effective contraception during therapy and for  months after completion of therapy
Pregnant women or nursing mothers are not eligible for this trial; patients of child bearing potential must use adequate contraception
Pregnant (positive pregnancy test) or lactating women will be excluded from the study; also, unwillingness to use effective means of contraception in subjects with child-bearing potential will be excluded from the study; women of child-bearing potential must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least  weeks prior to study entry, for the duration of study participation
Females of child-bearing potential who are pregnant or lactating or who are not using approved contraception
Pregnant (positive pregnancy test) or lactating; unwillingness to use effective means of contraception in subjects with child-bearing potential
Be of non-child bearing potential:
Patients of child-bearing potential must agree to use a medically approved contraception method until at least six weeks after the last study drug administration.
Patients with child bearing potential must agree to use adequate contraception
Use of an effective means of contraception in subjects of child-bearing potential
Non-child bearing potential or able to follow birth control requirements
Women of child-bearing potential and male subjects with female partners of child-bearing potential must be willing to use acceptable methods of contraception to avoid pregnancy (for example, oral, injectable, or implantable hormonal contraceptive, tubal ligation, intra-uterine device, barrier contraceptive with spermicide, or vasectomized partner) beginning before the first infusion of G- and for  months after the last infusion of G-
Females of child-bearing potential must agree to use adequate contraception and for  months after the last dose of study drug
If a sexually active male or a sexually active female of child-bearing potential, agrees to use dual (two concurrent) forms of medically accepted contraception from the time of consent until  months after the last dose of either ONT- or T-DM, whichever is longer.
Pregnancy, or unwillingness to use contraception if they have child bearing potential
Of non-child bearing potential:
Patient is of child bearing potential and is not willing to use, in combination with her partner, two highly effective methods of contraception or abstinence during treatment and for  months after the end of treatment
Child bearing potential: In this patient population, this pertains to the ability to conceive a child; eligible patients already have received prostatectomy, and therefore this risk is not applicable
Men of child bearing potential must be willing to consent to using effective contraception while on treatment and for at least  months thereafter
If a female of child bearing potential, willing to use adequate contraception (defined as double-method contraception, e.g. oral contraceptive usage by subject and condom by partner); non-child bearing potential is defined as being at least  years post-menopausal or being surgically sterile
Females: pregnant or breast feeding and if of child bearing potential (e.g. female of childbearing age that has not been amenorrheic for at least  consecutive month or surgically sterilized) not willing to use effective contraception
Patient of child-bearing potential is not willing to use adequate contraceptive precautions; adequate effective method of contraception are those which result in low failure rates, less than % per year, such as non-hormonal intrauterine device (IUD), condoms, sexual abstinence or vasectomized partner
Women of child bearing potential and men with partners of child bearing potential must agree to use effective contraception during therapy and for  months after completion of therapy
Pregnant or lactating females will be excluded from this trial; patients of child-bearing potential must use an effective form of contraception while on study
Pregnancy or breast-feeding (participants of child-bearing potential are eligible but must consent to using effective contraception during therapy and for at least  months after completing therapy)
Barrier contraceptive precautions are to be used throughout the trial by all study participants of child bearing potential.
Lactating or pregnant women or female patients of child-bearing potential (or male patients with such partners) not willing to use adequate contraception
Patients with child-bearing potential will agree to use contraception while on study and for  days from the date of the last therapy on protocol
Female subject is either postmenopausal for at least  year before the screening visit, is surgically sterilized or is of child-bearing potential; female subjects of child-bearing potential must agree to abstain from sexual activity or to use  medically approved contraceptive measures/regimens from the time of signing the informed consent form through  months after the treatment period
lactating or pregnant women or female patients of child-bearing potential (or male patients with such partners) not willing to use adequate contraception
Male and female patients of child-bearing potential unwilling to use effective means of contraception
Male and female patients of child-bearing potential unwilling to use effective means of contraception
Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study.
Subject is of child bearing potential and is not willing to use, in combination with her partner,  highly effective methods of contraception or abstinence during treatment and for  months after the end of treatment
Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of  months after study treatment.
Pregnancy or lactation; patients of child bearing age must agree to use adequate contraception
Women of child bearing potential not willing to use an effective contraceptive measure while on study
Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study.
Of non-child bearing potential:
Subjects with child-bearing potential agree to use effective means of contraception
Women of child bearing potential and their partners must use an acceptable method of contraception while enrolled on this study, and for a period of  months following study drug treatment. Patients unwilling or unable to follow this guideline will be excluded. Investigators should follow their Institutional standard regarding acceptable methods of contraception.
Female patients and male patients with female partners of child bearing potential must be using adequate contraception.
women of child-bearing potential and male patients with sexual partners of child-bearing potential unwilling to use highly effective methods of contraception during dosing and for a specified duration after stopping study treatment
Male and female patients of child bearing potential must use an effective contraceptive method during the course of the study
Male patients must use an effective barrier method of contraception during study and for  months following the last dose if sexually active with a female of child-bearing potential
Pregnant or lactating female or female of child-bearing potential not employing adequate contraception.
Women of child-bearing potential must use an effective form of contraception during study and for at least  months after completion of study treatment
Patients of reproductive potential (female of child bearing potential has not been postmenopausal for at least  consecutive months or not surgically sterile; male of child bearing potential has not been surgically sterile) must follow accepted birth control methods (e.g. barrier method) during treatment
Patients who are pregnant or nursing; subjects of child-bearing age have to use effective means of contraception
Female subject of child bearing potential is not willing to use two methods of highly effective contraception during treatment and for  months after the end of treatment
Of nonchild bearing potential:
Female patients of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening; male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential throughout the study and for three months following the last dose of selinexor
Has nursed a child within  months of study enrollment
Women of child bearing potential agree to use effective contraception during therapy and for  months after completion of therapy
Females of child bearing potential defined as not post-menopausal for  months or no previous surgical sterilization or breast-feeding must be willing to use an effective contraceptive measure until  days after the last dose of eltrombopag; males who have had sexual contact with female of child-bearing potential must be willing to use contraceptive techniques until  days after the last dose of eltrombopag
Female subject of child bearing potential must be willing to use, in combination with her partner,  forms highly effective contraception during treatment and for  month after the end of treatment
Female subject of child bearing potential is not willing to use highly effective contraception during treatment and for  months after the end of treatment (see section .)
Patients who are not practicing adequate contraception are ineligible if they are of child bearing potential
Women of child-bearing potential willing to practice  forms of contraception, one of which must be a barrier method until at least  days after the last dose of rapamycin
Patients who are not practicing adequate contraception if the participants are of child bearing potential
Participants of child-bearing age must use appropriate contraception (barrier, hormonal or post-menopausal) until one month after study medication ends
Of child-bearing age with intact reproductive organs
Use of an effective means of contraception in women of child-bearing potential
Women of child-bearing potential who are unable or unwilling to use an acceptable method of contraception.
Patients must have evidence of non-child-bearing potential.
must be willing to use appropriate contraception if of child-bearing potential
All female subjects of child bearing age must be either surgically sterile, postmenopausal for at least  year, or using an acceptable method of contraception. Adequate contraception for both male and female subjects must be used from the beginning of the screening period until at least  weeks after the last dose of study drug.
